EcoDrugPlus

Integrin Subunit Alpha V

Ensembl ID : ENSBMUG00000023000
Gene Symbol: ITGAV
3 Cross references
243 Possible Orthologues:

Integrin Subunit Beta 1

Ensembl ID : ENSBMUG00000015634
Gene Symbol: ITGB1
3 Cross references
301 Possible Orthologues:

Integrin Subunit Beta 3

Ensembl ID : ENSBMUG00000024929
Gene Symbol: ITGB3
3 Cross references
268 Possible Orthologues:

Integrin Subunit Beta 5

Ensembl ID : ENSBMUG00000010638
Gene Symbol: ITGB5
3 Cross references
211 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSBMUG00000017042
Gene Symbol: ITGB6
3 Cross references
205 Possible Orthologues:

Integrin Subunit Beta 7

Ensembl ID : ENSBMUG00000022408
Gene Symbol: ITGB7
3 Cross references
159 Possible Orthologues:

Integrin Subunit Beta 8

Ensembl ID : ENSBMUG00000017068
Gene Symbol: ITGB8
3 Cross references
207 Possible Orthologues:

Intercellular Adhesion Molecule 1-Like

Ensembl ID : ENSBMUG00000020740
Gene Symbol: LOC102278214
2 Cross references
69 Possible Orthologues:

Interleukin 1 Receptor Associated Kinase 4

Ensembl ID : ENSBMUG00000014337
Gene Symbol: IRAK4
3 Cross references
202 Possible Orthologues:

Interleukin 5

Ensembl ID : ENSBMUG00000014557
Gene Symbol: IL5
3 Cross references
91 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 1

Ensembl ID : ENSBMUG00000010416
Gene Symbol: IDH1
3 Cross references
234 Possible Orthologues:

Isocitrate Dehydrogenase (Nadp(+)) 2

Ensembl ID : ENSBMUG00000007161
Gene Symbol: IDH2
3 Cross references
261 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).